Abstract
GBA mutations are among the most common genetic risk factors for Parkinson disease (PD) worldwide. We aimed to identify genetic modifiers of the age at onset (AAO) in GBA-associated PD. The study included a genome-wide discovery phase, including a cohort of 79 patients with the GBA p.N370S mutation, and candidate validation and replication analyses of 8 SNPs in patients with mild (n = 113) and severe (n = 41) GBA mutations. Genotyping was performed using the Affymetrix human SNP 6.0 array and TaqMan assays. In the genome-wide phase, none of the SNPs passed the genome-wide significance threshold. Eight SNPs were selected for further analysis from the top hits. In all GBA-associated PD patients (n = 153), the BIN1 rs13403026 minor allele was associated with an older AAO (12.4 ± 5.9 years later, p = 0.0001), compared to patients homozygous for the major allele. Furthermore, the AAO was 10.7 ± 6.8 years later in patients with mild GBA mutations, (p = 0.005, validation group), and 17.1 ± 2.5 years later in patients with severe GBA mutations (p = 0.01, replication). Our results suggest that alterations in the BIN1 locus, previously associated with Alzheimer disease, may modify the AAO of GBA-associated PD. More studies in other populations are required to examine the role of BIN1-related variants in GBA-associated PD.
This is a preview of subscription content, access via your institution.
References
- 1.
Sidransky E, Nalls MA, Aasly JO et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 361:1651–1661
- 2.
Gan-Or Z, Giladi N, Rozovski U et al (2008) Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 70:2277–2283
- 3.
Gan-Or Z, Amshalom I, Kilarski LL et al (2015) Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology 84(9):880–887
- 4.
Gan-Or Z, Bar-Shira A, Gurevich T et al (2011) Homozygosity for the MTX1 c.184T>A (p. S63T) alteration modifies the age of onset in GBA-associated Parkinson’s disease. Neurogenetics 12:325–332
- 5.
Voight BF, Pritchard JK (2005) Confounding from cryptic relatedness in case-control association studies. PLoS Genet 1(3):e32
- 6.
Vacic V, Ozelius LJ, Clark LN et al (2014) Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes. Hum Mol Genet 23(17):4693–4702
- 7.
Nalls MA, Pankratz N, Lill CM et al (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet 46:989–993
- 8.
Gan-Or Z, Bar-Shira A, Mirelman A et al (2012) The age at motor symptoms onset in LRRK2-associated Parkinson’s disease is affected by a variation in the MAPT locus: a possible interaction. J Mol Neurosci 46:541–544
- 9.
Golub Y, Berg D, Calne DB et al (2009) Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. Parkinsonism Relat Disord 15:539–541
- 10.
Seshadri S, Fitzpatrick AL, Ikram MA et al (2010) Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303:1832–1840
- 11.
Jun G, Ibrahim-Verbaas CA, Vronskaya M et al (2015) A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry. doi:10.1038/mp.2015.23
- 12.
Moskvina V, Harold D, Russo G et al (2013) Analysis of genome-wide association studies of Alzheimer disease and of Parkinson disease to determine if these 2 diseases share a common genetic risk. JAMA Neurol 70(10):1268–1276
- 13.
Lambert JC, Ibrahim-Verbaas CA, Harold D et al (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 45(12):1452–1458
- 14.
Tan MS, Yu JT, Tan L (2013) Bridging integrator 1 (BIN1): form, function, and Alzheimer’s disease. Trends Mol Med 19:594–603
- 15.
Pienaar IS, Burn D, Morris C et al (2012) Synaptic protein alterations in Parkinson’s disease. Mol Neurobiol 45:126–143
- 16.
Nicot AS, Toussaint A, Tosch V et al (2007) Mutations in amphiphysin 2 (BIN1) disrupt interaction with dynamin 2 and cause autosomal recessive centronuclear myopathy. Nat Genet 39:1134–1139
Acknowledgments
This work was supported by Tel Aviv Sourasky Medical Center Grant of Excellence, by the Kahn Foundation, by the Chief Scientist of the Israeli Ministry of Health (Grant No. 3-4893), by the Legacy Heritage Biomedical Science Partnership Program of the Israel Science Foundation (Grant No.1922/08), and by the Michael J. Fox Foundation.
Author information
Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
All authors declare no conflict of interest.
Ethical standard
All participants signed an informed consent before entering the study. The Institutional and National Supreme Helsinki Committees for Genetic Studies approved the study protocols and the informed consents, which have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Gan-Or, Z., Amshalom, I., Bar-Shira, A. et al. The Alzheimer disease BIN1 locus as a modifier of GBA-associated Parkinson disease. J Neurol 262, 2443–2447 (2015). https://doi.org/10.1007/s00415-015-7868-3
Received:
Revised:
Accepted:
Published:
Issue Date:
Keywords
- BIN1
- GBA
- Genetics
- Parkinson disease